ASTRO’S First Evidence-based Clinical Practice Guidelines on Radiation Therapy for Primary Liver Cancers - 2021 Annual Meeting

ASTRO’S First Evidence-based Clinical Practice Guidelines on Radiation Therapy for Primary Liver Cancers - 2021 Annual Meeting is organized by American Society for Radiation Oncology (ASTRO).

Course opens: 03/01/2022
Course expires:02/28/2025

Description:
This cased-based panel focuses on the guideline recommendations and evidentiary basis for EBRT for HCC and IHC. In ASTRO’s first primary liver cancers guideline, recommendations address the: 1) role of EBRT in the definitive/non-transplant setting in HCC and IHC; 2) role of EBRT in the neoadjuvant setting prior to surgical resection or OLT for HCC; and 3) recommended techniques, dose-fractionation regimens, and OAR dose constraints.

In addition to ASTRO, the guideline task force included multidisciplinary representation from the American Society of Clinical Oncology and the Society of Surgical Oncology. The ASTRO guideline development process and the systemic review parameters for this guideline is also briefly presented. To make the course more interactive and to frame the recommendations addressed in this guideline, speakers present case conferences to solidify the understanding of the more complex and controversial topics. Speakers ask the audience to respond to the SA-CME questions to confirm their comprehension of the guideline information from the presentation.

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Identify and describe the clinically relevant clinical trials and data related to the use of EBRT for HCC and IHC for multiple clinical settings.
• Apply new evidence-based guideline recommendations to clinical practice.
• Discuss the limitations and knowledge gaps of EBRT and emerging technologies and treatments for HCC and IHC.